Catalog # 4907-MSM8
Product Datasheet

Recombinant CD73 (Immuno-Oncology Target) Antibody

Mouse Monoclonal Antibody [Clone rNT5E/2544]

Catalog No	Format	Size
4907-MSM8-P0	Purified Ab with BSA and Azide at 200ug/ml	20 ug
4907-MSM8-P1	Purified Ab with BSA and Azide at 200ug/ml	100 ug
4907-MSM8-P1ABX	Purified Ab WITHOUT BSA or Azide at 1.0mg/ml	100 ug


Applications	Tested Dillution	Note
Western Blot (WB)	2-4ug/ml	

Product Details

Clone	rNT5E/2544
Immunogen	Recombinant full-length human CD73 protein
Host	Mouse
Clonality	Monoclonal
Isotype / Light Chain	IgG1 / Kappa
Mol. Weight of Antigen	63.37kDa
Cellular Localization	Cell membrane
Species Reactivity	Human
Positive Control	A431|Prostate or Lung Carcinoma|U87MG or PC-3 cells. Tonsil

**Optimal dilution for a specific application should be determined.*

Product Images for Recombinant CD73 (Immuno-Oncology Target) Antibody



Western Blot Analysis of Human Kidney, Human Skin, Human Spleen and HepG2 lysates using CD73 Recombinant Mouse Monoclonal Antibody (rNT5E/2544).

Specificity & Comments

CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression, dysregulation of immune cell infiltrates and stimulates angiogenesis resulting in tumor spreading. CD73 is active on the last step of the degradation pathway, where it is the enzyme that actually degrades AMP into adenosine. CD73-blockade promotes anti-tumor immunity by reducing adenosine accumulation. Accordingly, anti-CD73 mAbs stimulate anti-tumor immunity and reduce tumor metastasis in mouse tumor models, and could enhance the efficacy of treatment with anti-PD1 or anti-CTLA4 antibodies.

Supplied As

200ug/ml of Ab produced in a mammalian-based expression system. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Storage and Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations and Warranty

This antibody is available for research use only and is not approved for use in diagnosis.There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.